In this paper, we report a case of recurrent glioblastoma (GBM) harboring BRAF V600E alteration who initially responded to BRAF and MEK inhibition and subsequently developed treatment resistance by histological transformation to gliosarcoma and acquired an emerging KRASG12D and NF1L1083R mutations. This evidence concerns the gene MAP2K7 and gliosarcoma.